Gremubamab

Modify Date: 2024-04-02 19:44:15

Gremubamab structure	Common Name	Gremubamab
	CAS Number	1800381-36-5	Molecular Weight	N/A
	Density	N/A	Boiling Point	N/A
	Molecular Formula	N/A	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of Gremubamab

Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections[1][2].

Name	Gremubamab

Description	Gremubamab (MEDI3902) is a humanized IgG1 kappa anti-PcrV/Psl monoclonal antibody. Gremubamab binds to the PA PcrV protein and Psl exopolysaccharide. Gremubamab has the potential for the research of pseudomonas aeruginosa infections[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> Bacterial
In Vivo	Gremubamab (1, 5, 15 mg/kg; i.v.; at 1 h postinfection) 改善兔急性肺炎模型的生存结果[2]。 Animal Model: Rabbits (acute pneumonia model)[2] Dosage: 1, 5, 15 mg/kg Administration: I.v.; at 1 h postinfection Result: Improved survival outcomes in a dose-dependent manner in a rabbit acute pneumonia model.
References	[1]. Chastre J, et al. Safety, efficacy, and pharmacokinetics of gremubamab (MEDI3902), an anti-Pseudomonas aeruginosa bispecific human monoclonal antibody, in P. aeruginosa-colonised, mechanically ventilated intensive care unit patients: a randomised controlled trial. Crit Care. 2022 Nov 15;26(1):355. [2]. Le HN, et al. Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models. Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19.

No Any Chemical & Physical Properties

Gremubamab

Use of Gremubamab

Names

Gremubamab Biological Activity

Chemical & Physical Properties